You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Design quality into products
Most drugs contain only one active ingredient but the number of combination drugs (with more than one active ingredient) are increasing, and presently form about ten percent of all drugs on the market.
This project aims to develop rules for the design, production and control of pharmaceutical products with an emphasis on such "poly pills". The difficulty in producing combination drugs is that the mixture they are created from has to be completely homogenous, since you do not want one pill to contain more of a certain ingredient than another. Researchers in this project have succeeded in creating a production process that achieves just that.
A big advantage of combination drugs is that they can decrease the impact of taking medication on the lives of patients; next to that, they can also contribute to making drugs more accessible. Distribution costs of medicines are usually relatively high, especially in developing countries. Introducing poly pills, distribution costs can be drastically decreased simply due to a decrease in the number of pills that have to be transported.
Full project title: Design quality into products
Start date: July 2007
End date: July 2011
Goal: Development of consistent and effective administration methods for pharmaceutical products with an emphasis on fixed dose combinations
Principal investigator: Kees van der Voort Maarschalk
Project size: 4 FTE's
Partners: Abbott, MSD, TNO Quality of Life, University of Groningen
Tofan Willemsz (project D6-203)
Blending of Agglomerates into Powders
“What TI Pharma can deliver from collaborations is more efficient healthcare, faster time to market and quicker patient benefit.”